US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
Panacos Pharmaceuticals Inc (EM) (PANC) 銘柄情報

Panacos Pharmaceuticals Inc (EM) (PANC)

0.000001

0.00

(0.00%)

終了 6月10日 5:00AM

Panacos Pharmaceuticals Inc (EM) (PANC) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.000001

( - )

買値

0.00

売値

0.00

出来高

-

0.00 日の範囲 0.00

0.000001 52 週間の範囲 0.000001

時価総額

前日終値

0.000001

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 120

発行済株式数

53,640,136

配当利回り

PER

-0

1 株当たり利益 (EPS)

-0.67

歳入

99k

純利益

-35.76M

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the viru... Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

本社

Watertown, United States

設立

1999

Panacos Pharmaceuticals Inc (EM) is listed in the Healthcare sector of the その他OTC with ticker PANC. The last closing price for Panacos Pharmaceuticals (EM) was US$0. Over the last year, Panacos Pharmaceuticals (EM) shares have traded in a share price range of US$ 0.000001 to US$ 0.000001.

Panacos Pharmaceuticals (EM) currently has 53,640,136 shares in issue. The market capitalisation of Panacos Pharmaceuticals (EM) is US$53.64 . Panacos Pharmaceuticals (EM) has a price to earnings ratio (PE ratio) of -0.00.

American Stock Exchange to Trade Options on Five Securities

NEW YORK, Oct. 17 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in options on Tuesday, October 18, 2005 on the...

Vitex Completes Corporate Name Change to Panacos Pharmaceuticals, Inc.

WATERTOWN, Mass., Aug. 18 /PRNewswire-FirstCall/ -- V.I. Technologies, Inc. (NASDAQ:VITX) ("Vitex" or "the Company"), a biotechnology company...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	1.0E-6	1.0E-6	1.0E-6	0	0	CS
26	0	0	1.0E-6	1.0E-6	1.0E-6	15	1.0E-6	CS
52	0	0	1.0E-6	1.0E-6	1.0E-6	11	1.0E-6	CS
156	-9.9E-5	-99	0.0001	0.0085	1.0E-6	6369	1.383E-5	CS
260	-0.000199	-99.5	0.0002	0.0085	1.0E-6	7841	9.459E-5	CS

PANC - Frequently Asked Questions (FAQ)

What is the current Panacos Pharmaceuticals Inc (EM) share price?

The current share price of Panacos Pharmaceuticals Inc (EM) is US$ 0.000001

How many Panacos Pharmaceuticals Inc (EM) shares are in issue?

Panacos Pharmaceuticals Inc (EM) has 53,640,136 shares in issue

What is the market cap of Panacos Pharmaceuticals Inc (EM)?

The market capitalisation of Panacos Pharmaceuticals Inc (EM) is USD 53.64

What is the 1 year trading range for Panacos Pharmaceuticals Inc (EM) share price?

Panacos Pharmaceuticals Inc (EM) has traded in the range of US$ 0.000001 to US$ 0.000001 during the past year

What is the PE ratio of Panacos Pharmaceuticals Inc (EM)?

The price to earnings ratio of Panacos Pharmaceuticals Inc (EM) is -0

What is the cash to sales ratio of Panacos Pharmaceuticals Inc (EM)?

The cash to sales ratio of Panacos Pharmaceuticals Inc (EM) is 0

What is the registered address of Panacos Pharmaceuticals Inc (EM)?

The registered address for Panacos Pharmaceuticals Inc (EM) is 134 Coolidge Avenue, Watertown, Massachusetts, 02472

Which industry sector does Panacos Pharmaceuticals Inc (EM) operate in?

Panacos Pharmaceuticals Inc (EM) operates in the Biotechnology & Life Sciences sector

FORDGT

Thanks, The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. ... It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos ( PANC )

Golden Cross

Golden Cross 6年前

$PANC Tier Change
Grey Market to Expert Market

FORDGT

Dark or Defunct
Caveat Emptor
Unable to Contact
Company is not able to provide disclosure to the public markets.
Dark or Defunct
Caveat Emptor
Unable to Contact

FORDGT

Volume(Heavy Day)
35,000
January 27, 2020 3:22pm

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

FORDGT

Price $0.001 Day's Change 0.001 (99,900.00%)

FORDGT

Volume: 6,125 @07/05/19 3:39:17 PM EDT

JohnnyBlaze

JohnnyBlaze 11年前

lol 0.0001 - 0.005

FORDGT

FORDGT 12年前

[bPanacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

FORDGT

FORDGT 12年前

.0013 this looks good to me... To late to buy it now just watch this one Panacos Pharmaceuticals Inc PANC:Grey Market (Common Stock)

FORDGT

FORDGT 12年前

breakout on the way http://www.barchart.com/opinions/stocks/PANC

FORDGT

FORDGT 12年前

Could Have Ebola Here This story will bring PANC back from the dead..

FORDGT

FORDGT 12年前

Up 11% today with no bid and no ask... Get ready something is going to happen...

FORDGT

FORDGT 12年前

sidedraft

sidedraft 12年前

PANC: Suspended by SEC

http://www.sec.gov/litigation/suspensions/2014/34-71465.pdf

Order:

http://www.sec.gov/litigation/suspensions/2014/34-71465-o.pdf

FORDGT

FORDGT 13年前

% Above Low (08/08/13 - 01/02/13)

1,036.36% A very nice move year to date.. They have taken out the bottom.. This is ready for the move up.. With the talk of world pandemic we should see another 1000% move in this one... Best of Luck,,

FORDGT

FORDGT 13年前

http://www.profitspi.com/stock-chart.aspx?id=PANC&ca=566914257

FORDGT

FORDGT 13年前

VERY NICE!!! SOON COMING CHINA EFFECT... LOAD UP... I MAY BE THE ONLY HOLDER IN THE WORLD.... WANT TO SHOOT AT THE MOON BUY WHAT YOU CAN AFFORD TO LOSE... Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

FORDGT

FORDGT 13年前

Balance Sheet
Total Cash (mrq): 26.89M
Total Cash Per Share (mrq): 0.50
Total Debt (mrq): 18.21M
Total Debt/Equity (mrq): 345.33
Current Ratio (mrq): 2.15
Book Value Per Share (mrq): 0.10

FORDGT

FORDGT 13年前

SOME ONE STILL LIKES IT! Other than myself....

FORDGT

FORDGT 14年前

Key Executive

Pay

Dr. Alan W. Dunton M.D., 57
Chief Exec. Officer, Pres and Director

637.00K

FORDGT

FORDGT 14年前

Panacos trading again 240,000 ....

BIG FACE HUNDREDS

BIG FACE HUNDREDS 14年前

anybody know what the current float is on PANC?

-Ed

I got time, they will vind PANC when it rock.

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

PANC HOD was .0185

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

Heavy bids.... PANC looks interesting ..

-Ed

200 Pieces and back to 0,01 pffff
Who is selling this S..T

FORDGT

FORDGT 14年前

The news is 3 we have had 3 candle sticks in a row... And 5 cent is not to far away... Looking very good... Or maybe it's ONE because this stock is now in the 1 % percent of all advancing stocks... check the link http://www.barchart.com/snapopinion/stocks/PANC

-Ed

low volume but whe got 0,016 now

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

Seems like she is going higher.

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

PANC : buyout rumor is unfounded..imo

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

Wachout for PANC breakout at .018 - .09

could see .025 real quick and then some.

Target could be .04- .06.

volume heavier...would like to see news

-Ed

The volume is growing day by day, have the 0,017 see on the boards

-Ed

0,015 on the boards, the train is starting

-Ed

Cant find real news but there is something good news comming.

FORDGT

FORDGT 14年前

That chart does look good... 5 cents looks possible this month..

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

Accumulation has been very bullish.

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

WEEKLY CHART - PANC

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

You were lucky...was a gift..enjoy it while this moves..you must someoen on your side

; )

-Ed

Wow i bought on 0,001 for $ 3000,- and today 0,013 on the boards :)

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

She looks like she wants to go higher for some reason

Would like to hear from the company

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

PANC - I know that...bought some today.

Is there a specific reason you like them? BIG PHARMA BUYOUT,etc?
Looks good with increasing volume.>Would like to add closer to .01

-Ed

Pharma's are money makers, i got them on 0,001 :) a lot

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

WHY DO YOU LIKE PANC?

-Ed

Dunno but i'll wait, the day comes for rocket time

OCKHAM'S RAZOR

OCKHAM'S RAZOR 14年前

PANC looking interesting here

YOu still bullish on it?

-Ed

last news for panc :)insert-text-here

-Ed

Hope they get higher, thz for the post.

-Ed

FORDGT

FORDGT 14年前

STEADY CLIMB !! http://www.profitspi.com/stock-chart.aspx?id=PANC&ca=1554458243

-Ed

0,018 its alive

FORDGT

FORDGT 14年前

Chart looking good...

Panacos Pharmaceuticals (EM)

Bond 2375% until 05/31/2...

Sinergiya Invest Holding...

Morgan Stanley DW ST Saturn Dpl

International bond 3.5% ...

iShares iBonds Dec 2028 ...

Zephyr Minerals

Invesco S&P Global Divid...

UBS S&P 500 Scored and S...

iSign Media Solutions

Ko Nts Car 11/04/2027

St Charles Resources

Nabaltec Ag Inh

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。